The Company hereby announces that on August 31, 2017, DiagnosTear Ltd. (“DiagnosTear”) announced the recruitment of a first participant for an additional clinical trial to examine a product based on the TeaRx ™ technology, which is used to diagnose, personalize treatment and monitoring Dry eye syndrome by examining the composition of the tear film. This trial is carried out as part of the regulatory approval processes of the point of care product (the “Trial” and “the Product”, respectively).
Link to complete article:
Link to Newsroom